SCHEMBL13409590

SCHEMBL13409590

CC(C)(C)OC(=O)CN(c1ccc2c(ccn2-c2cc(CO)ccn2)c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE1C Q14123 1/20 0.33
PDE3A Q14432 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.32
DGAT1 O75907 2/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13390456 0.93 NR1H2 (0.32) PKMHSD17B10PDE5APDE4APDE1A
SCHEMBL13390279 0.90 PKM (0.38) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390674 0.90 BRD9 (0.33) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390273 0.90 PKM (0.34) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390768 0.90 PKM (0.34) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390789 0.89 PKM (0.33) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390673 0.89 PKM (0.33) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL13390807 0.89 PKM (0.33) PKMHSD17B10TP53MAPTDGAT1
SCHEMBL3297315 0.89 KDM4C (0.34) PKMHSD17B10TP53DGAT1PSEN1
SCHEMBL13390554 0.88 KMT2A (0.36) PKMHSD17B10TP53DGAT1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed
WO-2008099000-A2 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 PKM 117/4885HSD17B10 2472/4885PDE5A 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.